Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04548648 · ClinicalTrials.gov registry record · Phase 2

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

A Phase 2 study of Central Nervous System Lymphoma, sponsored by UNC Lineberger Comprehensive Cancer Center.

Active
Registry status
Phase 2
Development phase
10
Enrollment target
3
Study locations

NCT04548648 is a Phase 2 study of Central Nervous System Lymphoma that is active but no longer recruiting, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 10 participants, below the 105-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04548648, a Phase 2 study of Central Nervous System Lymphoma, is active but no longer recruiting, sponsored by UNC Lineberger Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
10 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma. Although acalabrutinib has not been approved for the treatment of CNS lymphoma, it was approved for the treatment of another type of lymphoma (mantle cell), by the Food and Drug Administration (FDA). Acalabrutinib acts similar to another cancer drug called ibrutinib. lbrutinib was tested in several research trials for the management of CNS lymphomas, and the results were promising. Acalabrutinib and ibrutinib attack a similar target found in CNS lymphoma. Acalabrutinib may do a better job in attacking this target than ibrutinib. The study doctors will be looking to see if acalabrutinib can shrink cancer cells.

Conditions Studied

Central Nervous System Lymphoma

Interventions

  • DRUG Acalabrutinib

Study Locations (3)

North Carolina

  • Lineberger Comprehensive Cancer Center - Chapel Hill
  • Wake Forest University,The Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem

Florida

  • Moffit Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-10-15
Est. Completion 2030-03-14
Phase Phase 2

Sponsor

UNC Lineberger Comprehensive Cancer Center

366 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04548648

The ClinicalTrials.gov registry entry for NCT04548648 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Acalabrutinib is the first listed.

NCT04548648 reports 3 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Florida.

Frequently Asked Questions

What is clinical trial NCT04548648 about?

NCT04548648 is a clinical study titled "A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas". The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma. Although acalabrutinib has not been approved for the treatment of CNS lymp...

What is the current status of trial NCT04548648?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2020-10-15. Estimated completion is 2030-03-14.

What conditions does trial NCT04548648 study?

This clinical trial studies the following conditions: Central Nervous System Lymphoma.

What interventions are being tested in trial NCT04548648?

The interventions under investigation include: Acalabrutinib (DRUG).

Who is sponsoring clinical trial NCT04548648?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04548648 being conducted?

This trial has 3 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Central Nervous System Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Central Nervous System Lymphoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.